Skip to search formSkip to main contentSkip to account menu

3,4-diaminopyridine

Known as: Pyridine, 3,4-Diamino-, AMIFAMPRIDINE, 3,4-Pyridinediamine 
An organic compound derived from pyridine with potassium channel inhibition activity. Amifampridine inhibits potassium channel efflux, increasing the… 
National Institutes of Health

Related topics

Related topics

6 relations

Narrower (3)

FirdapseSC10amifampridine phosphate

Broader (2)

Potassium Channel Blockersdalfampridine
analogs & derivatives

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2007
Review
2007
The therapy of congenital myasthenic syndromes
Highly Cited
2006
Highly Cited
2006
Gateways to clinical trials.
Gateways to Clinical Trials are a guide to the most recent clinical trials in current literature and congresses. The data in the… 
Highly Cited
2004
Highly Cited
2004
Enhanced brain motor activity in patients with MS after a single dose of 3,4-diaminopyridine
Background: 3,4-Diaminopyridine (3,4-DAP), a potassium (K+) channel blocker, improves fatigue and motor function in multiple… 
Highly Cited
2002
Highly Cited
2002
Calcium-activated potassium channel SK1- and IK1-like immunoreactivity in injured human sensory neurones and its regulation by neurotrophic factors.
Calcium-activated potassium ion channels SK and IK (small and intermediate conductance, respectively) may be important in the… 
Highly Cited
2001
Highly Cited
2001
Persistence of botulinum neurotoxin A demonstrated by sequential administration of serotypes A and E in rat EDL muscle.
Highly Cited
1998
Highly Cited
1998
An open-labelled clinical and electrophysiological study of 3,4 diaminopyridine in the treatment of fatigue in multiple sclerosis.
We studied the electrophysiological parameters of motor performance in eight patients with multiple sclerosis and troublesome… 
Highly Cited
1996
Highly Cited
1996
Treatment with oral 3,4 diaminopyridine improves leg strength in multiple sclerosis patients
To examine the efficacy and toxicity of oral 3,4 diaminopyridine (DAP) in dosages up to 100 mg/day, 36 patients with multiple… 
Highly Cited
1991
Highly Cited
1991
N-methyl-D-aspartate receptor activation increases cAMP levels and voltage-gated Ca2+ channel activity in area CA1 of hippocampus.
Tetanic stimulation of the Schaffer collateral inputs into area CA1 of the hippocampus causes N-methyl-D-aspartate (NMDA… 
Highly Cited
1988
Highly Cited
1988
Altered response of fibroblasts from aged and Alzheimer donors to drugs that elevate cytosolic free calcium
Highly Cited
1984
Highly Cited
1984
Treatment of Lambert-Eaton syndrome: 3,4-diaminopyridine and pyridostigmine.
We used a new drug, 3,4-diaminopyridine, to treat five patients with the Lambert-Eaton syndrome, one with a carcinoma and four… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)